Personalized cancer dosing is an emerging approach that tailors drug dosages to the unique genetic, physiological, and metabolic characteristics of individual patients. Traditional chemotherapy often relies on standardized dosing based on body surface area or weight, which may not account for variations in drug metabolism, tumor biology, or patient sensitivity leading to suboptimal efficacy or increased toxicity.
Personalized dosing utilizes pharmacogenomics, therapeutic drug monitoring (TDM), and biomarker profiling to determine the most effective and safest drug concentrations for each patient. It considers factors such as genetic polymorphisms in drug-metabolizing enzymes, tumor mutation burden, organ function, and immune response.